ProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation

ProMetic Life Sciences Inc.’s (TSX:PLI) plasminogen drug Ryplazimä has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration, renewing investor interest in the Canadian bio-pharmaceutical company.

The Motley Fool

Today, shares of ProMetic Life Sciences Inc.(TSX:PLI) jumped more than 21% in early morning trading on news that its plasminogen drug, Ryplazimä, has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration (FDA), a drug which I covered in late December amid the beginning of a slide which has continued for ProMetic since the beginning of the year.

My thesis at the time was that the pipeline of drugs for ProMetic was not being accurately priced by the market, with the probability of success for the company’s Ryplazimä not fully appreciated by the market at the time. Despite the company’s stock price dipping another 35% since my initial article on the bio-pharmaceutical company, this most recent rebound following news of the FDA designation has sent ProMetic’s share price abruptly higher, reflecting much of the positive market sentiment stemming from the new designation.

The FDA has now provided three designations for Ryplazimä; in addition to a Rare Pediatric Disease designation, the drug has also received Orphan Drug status as well as Fast Track status — designations which highlight the importance of the drug and the current unmet need in the market for plasminogen treatments such as Ryplazimä.

If Ryplazimä indeed receives final FDA approval, the drug is in line to receive a rare pediatric disease priority voucher, which can be used to accelerate the review of an existing drug within the company’s pipeline or be sold off to a third party for a tidy profit. This is a rare asset handed out only in cases of significant unmet need: a scenario which has played out in favour of ProMetic’s Ryplazimä drug.

ProMetic’s chief executive officer Pierre Laurin spoke to the recent FDA announcement in a press release:

“We are pleased that RyplazimäTM has received this pediatric designation from the FDA. In addition to Ryplazimä’sTM orphan drug status, this designation represents another validation of the approach we have taken regarding our plasminogen’s clinical program…The pediatric designation also provides an important incentive for ProMetic to continue developing therapies addressing unmet medical needs for children with rare diseases. We look forward to continue to work closely with the FDA to bringing this innovative therapy to patients suffering from plasminogen deficiency.”

Bottom line

This is yet another step in the right direction for ProMetic — a company with a significant amount of promise in the Canadian bio-pharmaceutical space, one which has been hit hard in recent years. I will be watching this company closely over the coming weeks and months as new developments continue to roll in.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Chris MacDonald has no position in any stocks mentioned in this article.

More on Investing

A plant grows from coins.
Dividend Stocks

3 Dividend-Growth Champions That Could Keep Raising Payouts in Any Market

These three Canadian stocks with consistent dividend growth are excellent buys to boost your passive income and strengthen your portfolios.

Read more »

ways to boost income
Dividend Stocks

TFSA to $100K: 2 Dividend-Growth Stocks to Power a Tax-Free Fortune

Building a tax-free fortune through the TFSA is possible with two top-tier dividend-growth stocks.

Read more »

dividends can compound over time
Dividend Stocks

1 Magnificent Canadian Dividend Stock Down 21% to Buy and Hold for Decades

Down 21% from all-time highs, TD Bank is TSX dividend stock that offers a tasty dividend yield of 5.1% in…

Read more »

senior man smiles next to a light-filled window
Dividend Stocks

Canadians: 3 Big Changes Coming to CPP and OAS in 2025

If you don't expect to get enough CPP and OAS to retire, you can invest in ETFs like iShares S&P/TSX…

Read more »

Two seniors float in a pool.
Retirement

3 TSX Stocks That Can Turn Retirement Dreams Into Reality

Find out how to make your retirement dreams a reality by focusing on long-term investments and preparing for unforeseen circumstances.

Read more »

Lights glow in a cityscape at night.
Stock Market

Top TSX Transportation Stocks to Buy in 2025

Investing in quality TSX transportation stocks such as CP and TFI should help you deliver outsized gains in 2025 and…

Read more »

A worker overlooks an oil refinery plant.
Energy Stocks

Canadian Energy Stocks: Suncor Stock vs. Cenovus Stock

These two energy stocks are top options for investors wanting income that pays now and in the future, but which…

Read more »

woman retiree on computer
Dividend Stocks

2 Stocks Canadians in Their 50s Should Own

Choosing the right growth stocks when you are just a few years away from your retirement can have enormous implications…

Read more »